Classifying Chest Pain as Typical vs. Atypical Fails to Discriminate Acute Coronary Occlusion and Does Not Predict Mortality

José Nunes de Alencar1, Mariana Fuziy Nogueira De Marchi1, Kaliana Maria Nascimento Dias de Almeida1, Italo Menezes Ferreira1, Diandro Marinho Mota1, Hugo Ribeiro Ramadan1

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector.

Author approval: All authors have seen and approved the manuscript.

Data availability statement: Due to restrictions imposed by the institutional review board (IRB) related to patient confidentiality and data anonymization procedures, the datasets analyzed in this study are not publicly available.

Conflicts of Interest Disclosure: There is no conflict of interest to disclose.

Ethics approval: IRB number 76670223.4.0000.5462

Patient consent: N/A

Clinical trial registration: N/A

Permission to reproduce material from other sources: N/A

CORRESPONDING AUTHOR

José Nunes de Alencar Neto

Instituto Dante Pazzanese de Cardiologia

Avenida Dr. Dante Pazzanese No. 500, Vila Mariana

São Paulo 04012-091

Brazil

Tel: +551150856457

jose.alencar@dantepazzanese.org.br

ABSTRACT

Background: Current US guidelines discourage classifying chest pain as 'typical' or 'atypical,' yet this dichotomous approach remains widespread in clinical practice. We aimed to determine if this common classification has meaningful diagnostic or prognostic value for identifying acute coronary occlusion (ACO) in the emergency department (ED).

Methods: In a retrospective cohort of consecutive adults presenting with chest pain (January 2021–May 2025), we included patients who underwent ECG and high-sensitivity troponin I (hs-cTnI) testing. Chest pain was categorized as type A/B (definite/probable angina) or C/D (non-anginal). ACO was defined by door-to-balloon activation and/or peak hs-cTnI ≥ 5000 ng/L; sensitivity analyses used D2B alone or first hs-cTnI ≥ 11 ng/L. We calculated sensitivity, specificity, and likelihood ratios (LRs). A Bayesian latent-class model incorporated priors for index test accuracy and imperfect reference standard, yielding posterior medians (95% CrI). In-hospital death predictors were examined via multivariable logistic regression.

Results: Classifying pain as 'typical' demonstrated poor diagnostic utility for ACO, with a sensitivity of 0.69 (95% CI 0.66–0.71) and a specificity of 0.48 (95% CI 0.47–0.49). The resulting likelihood ratios were unhelpful for altering clinical probability (LR+ 1.33; LR- 0.65). These findings remained poor even after analysis with a Bayesian latent-class model designed to correct for an imperfect reference standard (posterior median LR+ 1.57; LR- 0.42). While associated with higher mortality in univariate analysis, 'typical' pain did not independently predict in-hospital death after multivariable adjustment (adjusted OR 1.28; 95% CI 0.91–1.81).

Conclusions: In this large, contemporary ED cohort, the common practice of labeling chest pain as 'typical' versus 'atypical' offers negligible value for either ruling in or ruling out ACO and fails to independently predict short-term mortality. This evidence strongly supports guideline recommendations to abandon these overly simplistic, dichotomous labels.

Introduction

The most recent American guideline on the evaluation of chest pain, the current European guideline on acute coronary syndromes, and the latest American guideline on myocardial infarction each advise against subdividing chest discomfort into the traditional "typical versus atypical".(1–3) These documents instead recommend describing pain in terms of its pre-test probability of ischemic origin, integrating the full clinical context rather than relying on a rigid semiological grid.

In the present work we therefore examined, in a large tertiary-care emergency department, how well the A–D classification discriminates between patients with and without acute coronary occlusion (ACO) and whether it predicts short-term mortality. Particular attention was paid to minimizing both work-up bias and incorporation bias—two shortcomings that plagued earlier studies.

Methods

Study design and setting

We conducted a prospective observational study in the adult emergency department of a university-affiliated tertiary hospital in São Paulo, Brazil. All data were gathered between January 2021 and May 2025. The institutional review board approved the protocol with a waiver of individual informed consent because data collection relied exclusively on routinely acquired clinical information. This study follows STARD-BLCM guidelines.(4)

Patient selection

All consecutive patients aged eighteen years or older who presented with a chief complaint of chest pain were screened. To be eligible, an individual had to undergo a twelve-lead electrocardiogram at presentation and have at least one high-sensitivity cardiac troponin I (hs-cTn-I) measurement recorded during the index visit. Patients were excluded if either ECG or troponin were not requested.

Chest-pain classification procedure

At first clinical contact, resident physicians coded the patient's symptom according to the four‑tier scheme endorsed by the Brazilian Society of Cardiology.(5) A presentation was labelled "definite angina" (type A) when the discomfort was retrosternal, precipitated by exertion, radiated to the shoulder, neck, or left arm, and abated within ≈ 10 minutes of rest or sublingual nitroglycerin. "Probable angina" (type B) shared most—but not all—of those features. "Probably non‑anginal pain" (type C) denoted atypical chest pain that failed to meet the angina criteria, whereas "definite non‑anginal pain" (type D) described discomfort unrelated to physical activity, suggestive of an extracardiac origin and unresponsive to nitrates. Residents were trained in this taxonomy during orientation, and their initial entries in the electronic medical record were usually verified by attending emergency physicians. For analytic purposes we treated the presence of type A or type B characteristics (definite or probable angina) as a positive index test (typical angina), whereas type C or type D pain was considered negative (atypical angina).

Definition of acute coronary occlusion

Our primary case definition aimed to capture true-positive occlusions while reducing verification bias. A patient was labelled as having ACO if the emergency team activated the door-to-balloon (D2B) protocol, which obliges emergent percutaneous coronary intervention. Because reliance on D2B alone may overlook occlusions without overt ST-segment elevation, we also classified as cases those whose peak hs-cTn-I reached or exceeded 5000 ng/L. Two pre-specified sensitivity analyses were undertaken: first, repeating all calculations after removing the troponin criterion, and second, redefining cases solely by a peak hs-cTn-I of at least 11 ng/L, the high-risk threshold employed by our laboratory. Controls were patients who did not trigger D2B activation and whose peak troponin remained below 5000 ng/L (or below 11 ng/L in the second sensitivity analysis).

Biochemical assays

Hs-cTnI was measured using the VITROS platform. Our laboratory reference interval categorizes values below the limit of quantification (LoQ), which is 1.5 ng/L, as very low risk. Values between 1.5 and 10.9 ng/L are considered minor elevations, while values above or equal to 11 ng/L are considered the 99th percentile value.

Outcomes

We assessed two sets of outcomes. Diagnostic performance—sensitivity, specificity, and positive and negative likelihood ratios—was calculated for the chest-pain test against the reference standard for ACO. Prognostic performance was evaluated by all-cause in-hospital mortality.

Data handling and statistical analysis

Clinical variables, laboratory values and outcome data were extracted via SQL queries into Microsoft Excel and analyzed with R version 4.5.0. Categorical variables are presented as counts and proportions; continuous variables as means with standard deviations or medians with inter-quartile ranges, as appropriate. Sensitivity and specificity were accompanied by exact (Clopper-Pearson) 95 percent confidence intervals.(6) Likelihood-ratio confidence intervals were derived with the log-method. Diagnostic metrics were re-computed in prespecified strata defined by sex and by age (<65 years vs ≥ 65 years). For prognostic analysis, we calculated crude odds ratios for death and produced multivariable logistic-regression models adjusting for sex and age. For each binary comorbidity we constructed a 2 x 2 contingency table and calculated a two-sided Pearson χ^2 statistic without Yates correction. When any expected frequency fell below five, the χ^2 approximation was replaced by Fisher's exact test. Statistical tests were two-sided and a P-value below 0.05 denoted significance.

To account for the recognized misclassification of our composite reference standard, we fitted a four-cell multinomial Bayesian latent-class model.

- Index test (type A/B vs C/D): Se ~ Beta(21, 9) and Sp ~ Beta(15, 16), expressing modest confidence in the accuracy suggested by our frequentist analysis (effective sample size ≈ 30) —an approach recommended by the STARD BLCM extension when reliable internal data exist.

- Composite reference test: Se ~ Beta(6, 5) and Sp ~ Beta(96, 5). For the sensitivity prior (Se), we adopted a vague Beta(6, 5) distribution, which centers around 0.55 but retains wide uncertainty. This choice reflects the known limitations of our composite case definition. Specifically, the sensitivity of ST-segment elevation (the primary trigger for door-to-balloon activation) for angiographic coronary occlusion has been estimated at just 43.6% in a recent meta-analysis.(7) We complemented this criterion with a peak hs-cTnI ≥ 5000 ng/L to capture occlusions that might not manifest ST elevation; however, the diagnostic sensitivity and specificity of that troponin threshold for ACO are not well established in the literature. Given this ambiguity, we intentionally specified a conservative, weakly informative prior that acknowledges substantial uncertainty in the composite reference standard's ability to detect true occlusions. For specificity (Sp), we used a more concentrated Beta(96, 5) prior, reflecting high confidence that patients who triggered D2B activation or had a troponin elevation above 5000 ng/L are unlikely to be false positives. This asymmetry in prior strength—vague for sensitivity, concentrated for specificity—was predetermined to align with empirical evidence and clinical expectations in the emergency care setting.

- Prevalence: a Beta (9, 291) prior (mean 0.03, effective sample size = 300) was retained, representing the best external estimate of ACO prevalence in undifferentiated chest-pain populations.

- Sampling and convergence: Three chains were run in rjags (3000 burn in, 9000 retained iterations, thinning = 3). Convergence was confirmed by Gelman–Rubin R hat ≤ 1.002, visual trace plot stability, effective sample sizes > 3700 for every target, and time series

Monte-Carlo SE ≤ 0.0033. Posterior medians and equal-tail 95% credible intervals (CrI) are reported.

- Sensitivity to conditional dependence: Because the index test and the composite reference share semiological information, we performed a secondary Bayesian run assuming a modest positive conditional correlation ($\rho = 0.20$) between their latent errors, implemented with the Sarmanov method. All other priors and sampling settings were left unchanged.

Sensitivity analysis

To probe the robustness of all frequentist estimates we re-ran the complete diagnostic work-up under three prespecified scenarios:

1. Reference-standard restriction – the gold standard was limited to D2B activation only.
2. Biochemical benchmark – cases were defined exclusively by a peak high-sensitivity troponin-T ≥ 11 ng/L, mirroring the CK-MB–based definition used by Bassan et al. in 2000.(8)
3. Alternative index-test definition – "positive" pain was narrowed to type A alone, while any combination of types B, C, or D constituted the negative group.

Results

Among 28167 emergency-department visits in which troponin and an EKG were requested in 2021-2025, 402 had < 18 years, 1430 were transferred from another hospital, and 11032 were excluded due to no reference to types A, B, C or D or every box was ticked "no". The remaining 15303 encounters, from 11490 unique patients, constituted the analytic cohort (Figure 1).

The median age of these patients was 62 years (inter-quartile range 53-71). Men accounted for 54.9% of the population and women for 45.1%. Additional baseline characteristics are summarized in Table 1.

Diagnostic performance in frequentist estimates

When the composite reference standard was applied, the 2 x 2 table consisted of 883 true positives, 400 false negatives (1283 cases), 7265 false positives, and 6755 true negatives (14020 controls). From these figures, the "type A or B" (typical) designation yielded a sensitivity of 0.688 (95% CI 0.662–0.714) and a specificity of 0.482 (95% CI 0.474–0.490). The positive likelihood ratio (LR+) was 1.33 (95% CI 1.17–1.50) and the negative likelihood ratio (LR−) 0.65 (95% CI 0.57–0.73).

Sex stratification produced broadly comparable figures. In women, sensitivity was 0.715 (95% CI 0.67–0.757) and specificity 0.525 (95% CI 0.513–0.547); LR+ 1.50 (95% CI 1.21–1.87) and LR− 0.54 (95% CI 0.44–0.67). In men, sensitivity reached 0.675 (95 % CI 0.642–0.706) and specificity 0.445 (95% CI 0.434–0.456); LR+ 1.22 (95% CI 1.05–1.41) and LR− 0.73 (95% CI 0.63–0.85).

Accuracy did not change with age. Participants younger than sixty five years showed a sensitivity of 0.682 and specificity of 0.496; LR+ 1.35 (95 % CI 1.14–1.61) and LR− 0.64 (95 % CI 0.54–0.76). For those sixty five years or older, sensitivity was 0.694 and specificity was 0.463; LR+ 1.29 (95% CI 1.09–1.54) and LR− 0.66 (95% CI 0.56–0.79).

Sensitivity analysis

When the reference standard was restricted to D2B activation alone, the 2 × 2 table contained 73 true positives, 19 false negatives, 8075 false positives and 7136 true negatives. Sensitivity was 0.793 (95 % CI 0.696–0.871) while specificity was 0.469 (95 % CI 0.461–0.477). LR+ was 1.49 (95 % CI 0.90–2.48) and LR− 0.44 (95 % CI 0.27–0.73).

Re defining cases solely by a peak troponin I ≥ 11 ng/L reduced sensitivity to 0.532 (95% CI 0.524–0.540) and yielded a specificity of 0.464 (95% CI 0.386–0.543). Under this biochemical benchmark LR+ was 0.99 (95% CI 0.73–1.35) and LR− 1.01 (95% CI 0.74–1.37).

Finally, we re‑specified the index test to treat type‑A pain alone as "positive," lumping types‑B,‑C, and‑D together as "negative." Under the composite reference standard this definition achieved a sensitivity of‑0.314‑(95%‑CI‑0.289–0.340) and a markedly higher specificity of‑0.849‑(95%‑CI‑0.843–0.855). The resulting LR+ rose to‑2.08‑(95%‑CI‑1.83–2.36) and LR- was 0.81‑(95%‑CI‑0.71–0.92).

Diagnostic performance in Bayesian estimates

Bayesian latent‑class analysis that incorporated weighted priors for the imperfect reference standard produced a posterior median sensitivity of‑0.791 (95%‑CrI‑0.728–0.858) and a posterior median specificity of‑0.498 (95%‑CrI‑0.487–0.513) for the type‑A/B designation.‑The corresponding median LR+ was‑1.577 (95%‑CrI‑1.437–1.736), whereas the median LR– was‑0.420 (95%‑CrI‑0.28–0.55).‑All Gelman–Rubin R-hat statistics were ≤‑1.002, effective sample sizes exceeded 3700 for every parameter, and the largest time‑series Monte‑Carlo standard error was 0.0033, indicating excellent chain convergence and negligible simulation error. Diagnostic performance is summarized in Figure 2.

Regarding conditional-dependence, when a correlation of ρ‑=‑0.20 was imposed between the errors of the index and reference tests, the posterior median sensitivity was 0.794 (95%‑CrI‑0.731–0.861) and specificity 0.499 (95%‑CrI‑0.489–0.513); LR+‑1.587 (95%‑CrI‑1.499–1.743) and LR-‑0.412 (95%‑CrI‑0.276–0.542). Convergence remained excellent (all R‑hat‑≤‑1.002; effective sample sizes‑>‑5500). These figures are essentially super‑imposable on the base‑case model, indicating that modest conditional dependence does not materially alter the diagnostic verdict.

Prognostic performance

There were 150 in-hospital deaths among the analytic cohort. In univariate models, chest-pain classified as typical (versus atypical) was associated with higher mortality (OR 1.48; 95% CI 1.07–2.07). However, after adjusting for all covariates in a multivariable logistic regression, the association between type

A/B pain and death was attenuated and no longer statistically significant (adjusted OR 1.28; 95% CI 0.91–1.81). A BMI ≥ 30 kg/m² emerged as a strong independent predictor of in-hospital mortality (adjusted OR 4.55; 95% CI 2.99–6.76). Established peripheral artery disease (adjusted OR 2.87; 95% CI 1.56–4.92), heart failure (adjusted OR 2.35; 95% CI 1.64–3.33), and valvular heart disease (adjusted OR 2.22; 95% CI 1.34–3.52) also remained significant in the fully adjusted model. (Table 2).

Age remained independently predictive of death—each additional year of age was associated with a 3% increase in odds of in-hospital mortality (adjusted OR 1.03 per year; 95% CI 1.01–1.04). By contrast, first troponin ≥ 99th percentile, sex, and smoking were not included in the final multivariate model due to collinearity or lack of association when all other variables were accounted for.

Discussion

The latest U.S. chest pain guideline explicitly discourages a dichotomous "typical versus atypical" mindset and urges clinicians to weigh individual semiological elements and contextual probability.(1) Our data show that the global label "typical" conveys very limited incremental information when modern biochemical and angiographic standards are applied.

Bassan and colleagues(8) reported a sensitivity of 94% and a specificity of 52% for the A/B schema in 2000, findings widely quoted in Brazilian textbooks and triage protocols. However, their case definition required an elevated CK MB, which was not measured in patients assigned to type D, thereby locking the semiology into both incorporation and work up bias. By contrast, we defined acute coronary occlusion as either a D2B activation with angiographic evidence of an occluded vessel or a peak high sensitivity troponin I ≥ 5000 ng/L.(9) This dual criterion recognizes that ST segment–elevation is an imperfect surrogate for occlusion and partially mitigates the risk of missing non ST elevation occlusions that never reach the catheterization laboratory.(10) Sensitivity analyses—one dropping the troponin criterion, the other using a biochemical cut off of 11 ng/L alone—showed that likelihood ratios were still not helpful, underscoring the inherent weakness of this semiology rather than flaws in adjudication.

A more recent registry study of unstable angina found that type A pain predicted the decision to pursue invasive stratification.(11) That observation likely represents a form of collinearity bias: the semiology helps drive the decision to catheterize, and catheterization then becomes the outcome under study. Our design, anchored in objective biochemical thresholds and procedural activations avoids this circularity.

Notably, the American guideline cites a likelihood ratio of 4.26 for pain radiating to both arms—one isolated descriptor—while none of our analyses produced an LR+ above 1.65 for the composite A/B label. Likewise, our LR− never fell below 0.36, far from the < 0.1 benchmark considered helpful to rule out disease.(12) Table 3 juxtaposes our key likelihood ratios with those thresholds.(13)

A key strength of our work is the application of a Bayesian latent class model to account for misclassification within the composite reference standard. This approach allowed the data to "speak for itself" by integrating prior knowledge—specifically, modest confidence in the index test's accuracy combined with more certain expectations regarding the specificity of the composite reference test—into a cohesive probabilistic framework. After accounting for misclassification in the reference standard and adopting a low but plausible prior prevalence (≈ 3%), the posterior median LR+ was 1.57, whereas the median LR- was 0.42. Those figures closely mirror the best available aggregated evidence: Fanaroff's landmark meta analysis of six heterogeneous studies (≈ 14000 patients, $I^2 = 98\%$) reported an overall LR+ of 1.9 (95 % CI 0.94–2.9) and an LR- of 0.52 (95 % CI 0.35–0.69).(13) The wide heterogeneity in that review stemmed mostly from inconsistent definitions of "typical" pain—an observation that links with our finding that type based labels encode far more clinician gestalt than textbook criteria. Indeed, the modest Bayesian LR- in our data likely reflects the tacit synthesis physicians apply when designating pain as type C or D—subtle vocal inflections, patient behavior, risk factor burden and on the spot ECG interpretation—much as Bassan's original four tier construct captured nuances no rigid checklist could codify.(8) Our Bayesian model, by letting the data rather than a single "truth" table guide the posterior, may therefore be tapping into that

clinical intuition. Even so, whatever tacit knowledge is wrapped into the A/B label, it does not propel LR+ anywhere near the >10 threshold needed for a confident rule-in, and its potential rule-out value remains unacceptably fragile.

Prognostic perspective

In our univariate analysis, chest-pain classified as typical was associated with higher in-hospital mortality (OR 1.48; 95% CI 1.07–2.07). However, once we adjusted for age, sex, BMI ≥ 30 kg/m², and key cardiovascular comorbidities, type A/B pain no longer predicted death (adjusted OR 1.28; 95% CI 0.91–1.81).

Strengths and limitations

The main limitation of the present work is the small proportion of true acute-occlusion cases—191 out of 15303 encounters, or only 1.2% of the analytic cohort. A second limitation stems from case adjudication: ideally, an OMI diagnosis is established prospectively from high-fidelity data: immediate ECG interpretation, serial high-sensitivity troponin curves, detailed coronary angiography including TIMI flow, and complementary imaging such as echocardiography. In a retrospective database many of these elements are incomplete or absent, compelling us to adopt a pragmatic, more liberal definition of occlusion that combined door-to-balloon activation with a troponin peak ≥5000 ng/L. Although this strategy mitigates classic work-up bias, it may admit false-positive cases and almost certainly misses some false-negative occlusions. We therefore performed two sensitivity analyses—D2B-only and troponin ≥11 ng/L—to test the robustness of our findings across alternative reference standards.

Missing data present a further limitation: 44% of otherwise eligible visits lacked usable A–D coding, either because no chest-pain type was recorded or every box was marked "no." However, this reflects real-world documentation habits and may enhance external validity.

These limitations must be weighed against several strengths. First, the cohort is consecutive and unselected, representing everyday emergency-department practice rather than a curated registry. Second, we intentionally designed the

adjudication hierarchy to minimize both incorporation bias (the pain label itself never entered the case definition) and work-up bias (by including a biochemical criterion that captures non-ST-elevation probable occlusions). Third, all calculations were repeated under multiple reference scenarios, and the likelihood ratios remained uniformly modest, underscoring the intrinsic weakness of the A/B label rather than any single definitional choice.

Conclusions

In a consecutive cohort of more than fifteen thousand emergency-department presentations, the traditional typical versus atypical chest-pain designation identified acute coronary occlusion with a sensitivity of roughly 68% but a specificity of 48%, translating to likelihood ratios (LR+ ≈ 1.3; LR- ≈ 0.6) that scarcely altered pre-test probability. These metrics remained weak across sex and age strata and under three alternative case definitions.

A Bayesian latent-class analysis that explicitly corrected for misclassification in the reference standard reached the same clinical result: the posterior LR+ centered at 1.5 and the posterior LR- at 0.4. Taken together with current guideline advice and earlier methodological critiques, these data show that typical versus atypical classification confers negligible diagnostic or prognostic value in modern practice. Emergency departments should retire global pain labels and instead anchor triage on granular symptom descriptors, rapid high-sensitivity biomarkers and validated risk tools.

REFERENCES

1. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 30 de novembro de 2021;144(22):e368–454.

2. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 12 de outubro de 2023;44(38):3720–826.

3. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 7 de abril de 2021;42(14):1289–367.

4. Kostoulas P, Nielsen SS, Branscum AJ, Johnson WO, Dendukuri N, Dhand NK, et al. Reporting guidelines for diagnostic accuracy studies that use Bayesian latent class models (STARD-BLCM). Stat Med. 15 de outubro de 2017;36(23):3603–4.

5. Nicolau JC, Feitosa GS, Petriz JL, Furtado RH de M, Précoma DB, Lemke W, et al. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. Arq Bras Cardiol. 117(1):181–264.

6. Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial. Biometrika. 1934;26(4):404–13.

7. de Alencar JN, Scheffer MK, Correia BP, Franchini KG, Felicioni SP, Marchi MFND. Systematic review and meta-analysis of diagnostic test accuracy of ST-segment elevation for acute coronary occlusion. Int J Cardiol [Internet]. 19 de fevereiro de 2024 [citado 6 de março de 2024];0(0). Disponível em: https://www.internationaljournalofcardiology.com/article/S0167-5273(24)00335-8/abstract

8. Bassan R, Scofano M, Gamarski R, Dohmann H, Pimenta L, Volschan A, et al. Dor Torácica na Sala de Emergência. A Importância de uma Abordagem Sistematizada. 1º de janeiro de 2000;

9. McLaren J, de Alencar JN, Aslanger EK, Meyers HP, Smith SW. From ST-Segment Elevation MI to Occlusion MI. JACC Adv. novembro de 2024;3(11):101314.

10. Alencar JN de, Meyers HP, McLaren JTT, Smith SW. No false negative paradox in STEMI-NSTEMI diagnosis. Heart. 1º de novembro de 2024;110(21):1247–9.

11.   Prata MA, Ohe LN, Vilalva KH, Lemos LFM, Smanio PEP. Avaliação Crítica do Manejo da Angina Instável em Pronto-Socorro Terciário de Cardiologia. Arq Bras Cardiol. 21 de março de 2024;121(3).

12.   Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 17 de julho de 2004;329(7458):168–9.

13.   Fanaroff AC, Rymer JA, Goldstein SA, Simel DL, Newby LK. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA. novembro de 2015;314(18):1955–65.

TABLES

TABLE 1

Variable	Cases n (%)	Controls n (%)	p-value
Smoking	191 (14.9%)	1520 (10.8%)	<0.0001
Stroke	72 (5.6%)	842 (6.0%)	0.5672
BMI ≥ 30	226/774 (29.2%)	613/2006 (30.6%)	0.4840
Hypertension	1057 (82.4%)	10268 (73.3%)	<0.0001
Diabetes Mellitus	396 (30.9%)	3782 (27.0%)	0.0028
Dyslipidemia	843 (65.7%)	7782 (55.5%)	<0.0001
Peripheral Arterial Disease	55 (4.3%)	321 (2.3%)	<0.0001
Valvular Heart Disease	58 (4.5%)	907 (6.5%)	0.0060
Heart Failure	307 (23.9%)	2730 (19.5%)	<0.0001
Coronary Artery Disease	786 (61.3%)	5831 (41.6%)	<0.0001
Chronic Kidney Disease	166 (12.9%)	943 (6.7%)	<0.0001
Chagas Disease	21 (1.6%)	168 (1.2%)	0.1734

Legend: Baseline prevalence of selected comorbidities among ACO "cases" (door-to-balloon activation and/or peak hs-cTnI ≥ 5000 ng L^{-1}) versus "controls" (no ACO). Categorical variables are presented as n (%). p-values derive from a two-sided Pearson χ^2 test; Fisher's exact test was used when any expected cell count was < 5. Missing values (e.g., BMI) were excluded from each comparison.

TABLE 2.

Variable	Univariate OR	Univariate 95% CI	Multivariate OR	Multivariate 95% CI
Chest pain A/B vs. C/D	1.48	1.07 – 2.07	1.28	0.91 – 1.81
IMC ≥ 30	5.20	3.48 – 7.59	4.55	2.99 – 6.76
Peripheral Artery Disease	4.55	2.54 – 7.59	2.87	1.56 – 4.92
Heart Failure	3.40	2.46 – 4.70	2.35	1.64 – 3.33
Chagas Disease	3.41	1.32 – 7.17	2.25	0.84 – 5.02
Chronic Kidney Disease	2.85	1.84 – 4.28	1.38	0.87 – 2.14
Valvular Heart Disease	2.59	1.60 – 4.00	2.22	1.34 – 3.52
Hypertension	2.30	1.47 – 3.80	1.26	0.76 – 2.17
Stroke	2.03	1.18 – 3.28	1.41	0.81 – 2.31
Dyslipidemia	1.94	1.37 – 2.79	1.05	0.70 – 1.59
Diabetes Mellitus	1.84	1.32 – 2.54	1.29	0.91 – 1.82
Coronary Artery Disease	1.68	1.22 – 2.33	1.02	0.71 – 1.49
Age	1.04	1.02 – 1.05	1.03	1.01 – 1.04
First troponin ≥ 99th percentile	1.64	0.37 – 28.9	-	-
Smoking	1.37	0.85 – 2.11	-	-
Sex (Male)	1.07	0.78 – 1.49	-	-

Legend: Univariate and multivariable logistic regression analyses evaluating predictors of in-hospital mortality.

TABLE 3.

Finding (index test)	LR+ (95 %CI / CrI)	LR- (95 %CI / CrI)	Condition compared
Typical chest pain (Bayesian, present study)	1.57 (1.43 – 1.73)	0.42 (0.28 – 0.55)	ACO
"Typical" chest pain (heterogeneous definition)	1.9 (0.94 – 2.9)	0.52 (0.35 – 0.69)	ACS
Radiation to both arms	2.6 (1.8 – 3.7)	0.93 (0.89 – 0.96)	ACS
Pain similar to prior ischaemia	2.2 (2.0 – 2.6)	0.67 (0.60 – 0.74)	ACS
Change in pain pattern ≤ 24 h	2.0 (1.6 – 2.5)	0.84 (0.79 – 0.90)	ACS
Worse with exertion	1.5 – 1.8	0.66 – 0.83	ACS
Radiation to neck or jaw	1.5 (1.3 – 1.8)	0.91 (0.87 – 0.95)	ACS
Recent episode of similar pain	1.3 (1.1 – 1.4)	0.80 (0.71 – 0.90)	ACS
Radiation to left arm	1.3 (1.2 – 1.4)	0.88 (0.81 – 0.96)	ACS
Radiation to right arm	1.3 (0.78 – 2.1)	0.99 (0.96 – 1.00)	ACS
Associated diaphoresis	1.3 – 1.4	0.91 – 0.93	ACS
Burning quality	1.0 – 1.4	0.97 – 1.00	ACS
Nausea or vomiting	0.92 – 1.1	0.98 – 1.00	ACS
Palpitations	0.71 (0.37 – 1.3)	1.00 (0.98 – 1.10)	ACS
Syncope	0.55 (0.39 – 0.76)	1.10 (1.10 – 1.10)	ACS
Pleuritic character	0.35 – 0.61	1.10 – 1.20	ACS

Legend. Selected chest‐pain descriptors (from Fanaroff's meta-analysis)(13) and their diagnostic value. Abbreviations: LR+ = positive likelihood ratio; LR= = negative likelihood ratio; ACS = acute coronary syndrome (definitions varied across source studies); ACO = acute coronary occlusion (door‐to‐balloon activation or peak hs‐cTnI ≥ 5000 ng/L in the present study). Ranges without parentheses indicate the span of individual‐study estimates when a pooled CI was not reported.

FIGURES

Figure 1.

Legend: Flow of patients through the study.

Figure 2.

Legend: Positive and negative likelihood ratios for chest-pain type A/B (typical) under different reference definitions. Red markers and vertical lines represent the frequentist point estimates and 95% confidence intervals; blue markers and vertical lines represent Bayesian posterior medians and 95% credible intervals. From left to right: (1) door-to-balloon (D2B) activation and/or peak hs-cTnI ≥ 5000 ng L^{-1}, (2) D2B activation only, (3) peak troponin ≥ 99th percentile, and (4) Bayesian latent-class model ($\rho = 0$). The horizontal dashed line at $LR^+ = 1.0$ indicates no change in post-test probability.

Study population

Encounters undergoing ECG + hs-cTnI
in the ED between 2021 and 2025
(n = 28 167)

Hierarchical Exclusion

Excluded (n = 12 864)
• Age < 18 y (n = 402)
• Transfer from other hospital (n = 1 430)
• Chest-pain type undocumented
or all boxes 'no' (n = 11 032)

Analysis

Analytic cohort
n = 15 303 encounters
(11 490 unique patients)